| |
HCV Genotype 3 Is Associated With an Increased Risk of Cirrhosis and Hepatocellular Cancer in a National Sample of U.S. Veterans With HCV
|
| |
| |
Download the PDF here - (07/16/14)
Hepatology 2014
Fasiha Kanwal,1,2 Jennifer R. Kramer,1,3 Jawad Ilyas,2 Zhigang Duan,3 and Hashem B. El-Serag1,2
Data show that viral genotype 1 may increase the risk of cirrhosis and hepatocellular
carcinoma (HCC) compared to genotype 2 in patients with chronic hepatitis C virus
(HCV) infection. However, the effect of HCV genotype 3 on cirrhosis and HCC risk is
uncertain. We identified patients with active HCV infection, confirmed by positive polymerase chain reaction (PCR) and a known HCV genotype, from the VA HCV Clinical
Case Registry between 2000 and 2009. We examined the effect of HCV genotype on the
risk of cirrhosis and HCC in a Cox proportional hazards model adjusting for patients'
age, period of service (World War I/II, Vietnam era, post-Vietnam era), race, gender,
human immunodeficiency virus (HIV) infection, alcohol use, diabetes, body mass index,
and antiviral treatment receipt. Of the 110,484 patients with active HCV viremia,
88,348 (79.9%) had genotype 1, 13,077 (11.8%) genotype 2, 8,337 (7.5%) genotype 3,
and 1,082 (0.9%) patients had genotype 4 infection. Despite being younger, patients
with genotype 3 had a higher risk of developing cirrhosis (unadjusted hazard ratio
[HR]51.40, 95% confidence interval [CI]51.32-1.50) and HCC (unadjusted
HR51.66, 95% CI51.48-1.85) than HCV genotype 1 patients. After adjustment for
prespecified demographic, clinical, and antiviral treatment factors, the risk of cirrhosis
and HCC was 31% (adjusted HR51.31, 95% CI51.22-1.39) and 80% (adjusted
HR51.80, 95% CI51.61-2.03) higher in patients with genotype 3 compared to genotype
1 infected patients. Conclusion: HCV genotype 3 is associated with a significantly
increased risk of developing cirrhosis and HCC compared to HCV genotype 1. This
association is independent of patients' age, diabetes, body mass index, or antiviral treatment.
|
|
| |
| |
|
|
|
